Effect of puerarin on human choriocarcinoma cells

• Authors: Lidao Bao , Yi Wang , Ruilian Ma , Xianhua Ren , Haijun Lv , Agula B
• Languages of publication: EN

Abstracts

EN

Objective: To discuss the effect of puerarin
on human choriocarcinoma cells. Methods: Survival
rates under puerarin monotherapy, fluorouracil (5-FU)
monotherapy and puerarin in combination with 5-FU
were detected by MTT assay. Apoptotic morphology was
observed with Hoechst 33258 staining. Apoptosis rates
were detected with flow cytometry. Expressions of AKT,
mechanistic target of rapamycin (mTOR), and P70S6K
mRNAs and phosphorylated proteins were detected by
RT-PCR and Western blot. Tumor-bearing mice were
administered puerarin and puerarin+5-FU, and serum
levels of β-human chorionic gonadotropin (β-HCG) were
measured. Results: Proliferation inhibition and apoptosis
rates of JEG-3 cells were positively correlated with puerarin
concentration, which increased in the puerarin+5-FU
group. Expression levels of AKT, mTOR, P70S6K mRNAs,
and phosphorylated proteins decreased significantly
after action of puerarin at different concentrations.
With increasing puerarin concentration, expression
of cleaved-caspase-3 in JEG-3 cells increased, whereas
that of Bcl-2 decreased. Puerarin significantly inhibited
tumor growth in choriocarcinoma-bearing SCID mice.
Serum β-HCG levels were significantly lower than those of
control group after administration. Magnitude of β-HCG
decline was positively correlated with concentration.
Conclusion: Puerarin+5-FU inhibited proliferation of JEG-3
choriocarcinoma cells and promoted their apoptosis,
being associated with the mTOR signaling pathway.

Keywords

EN

puerarin; fluorouracil; JEG-3; choriocarcinoma

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2014
• Volume: 10
• Issue: 1

Dates

accepted

19 - 3 - 2015

online

28 - 4 - 2015

received

31 - 1 - 2015

Contributors

author

Lidao Bao

• Department of Pharmacy,
  Affiliated Hospital of Inner Mongolia Medical University, Hohhot
  010059, PR China

author

Yi Wang

• Department of Pharmacy,
  Affiliated Hospital of Inner Mongolia Medical University, Hohhot
  010059, PR China

author

Ruilian Ma

• Department of Pharmacy,
  Affiliated Hospital of Inner Mongolia Medical University, Hohhot
  010059, PR China

author

Xianhua Ren

• Department of Pharmacy,
  Affiliated Hospital of Inner Mongolia Medical University, Hohhot
  010059, PR China

author

Haijun Lv

• Department of Scientific
  Research, Affiliated Hospital of Inner Mongolia Medical University,
  Hohhot 010059, PR China

author

Agula B

• College of Mongolian Medicine, Inner Mongolia Medical
  University, Hohhot 010059, PR China

References

• [1] Abbasi N.Z., Zahur Z., Sheikh A.S., Khan A.A., Ahmed F.,Memon K.H., et al., Testicular choriocarcinoma: diagnosedon cervical lymph node biopsy, J. Pak. Med. Assoc., 2014, 63,1544-1546.
• [2] Yazgan Y., Öncü K., Kaplan M., Tanoğlu A., Küçük I., ÖzarıH.O., et al., Upper gastrointestinal bleeding as an initialmanifestation of metastasis secondary to choriocarcinoma,Turk. J. Gastroenterol., 2014, 24, 565-567.[WoS]
• [3] Chen Y., Qian H., Wang H., Zhang X., Fu M., Liang X., et al.,Ad-PUMA sensitizes drug-resistant choriocarcinoma cells tochemotherapeutic agents, Gynecol. Oncol., 2007, 107, 505-512.[WoS][Crossref]
• [4] Kawamura K., Kawamura N., Okamoto N., Manabe M.,Suppression of choriocarcinoma invasion and metastasisfollowing blockade of BDNF/TrkB signaling, Cancer Med., 2014,2, 849-861.[WoS][Crossref]
• [5] Sorbi F., Sisti G., Pieralli A., Di Tommaso M., Livi L., BuccolieroA.M., et al., Cervicoisthmic choriocarcinoma mimickingcesarean section scar ectopic pregnancy, J. Res. Med. Sci.,2014, 18, 914-917.
• [6] Dach J., Jeffrey Dach, MD: The Transition to a Natural MedicinePractice, Altern. Ther. Health M., 2014, 20, 52-57.
• [7] Ni Y., Zhuang H., Kokot S., A High Performance Liquid Chromatographyand Electrospray Ionization Mass SpectrometryMethod for the Analysis of the Natural Medicine, ForsythiaSuspensa, Anal. Lett., 2014, 47, 102-116.[WoS][Crossref]
• [8] Niitsu T., Okamoto H., Iyo M., Behavioural and psychologicalsymptoms of dementia in an Alzheimer’s disease casesuccessfully treated with natural medicine: association withgonadotropins, Psychogeriatrics, 2013, 13, 124-127.[WoS][Crossref]
• [9] Li H., Dong L., Liu Y., Wang G., Zhang L., Qiao Y., Comparisonof two approaches of intestinal absorption by puerarin, J.Pharmacol. Toxicol. Methods, 2014, 70, 6-11.[Crossref][WoS]
• [10] Pignataro G., Capone D., Polichetti G., Vinciguerra A., GentileA., Di Renzo G., et al., Neuroprotective, immunosuppressantand antineoplastic properties of mTOR inhibitors: current andemerging therapeutic options, Curr. Opin. Pharmacol., 2011, 11,378-394.[Crossref][WoS]
• [11] Gentzler R.D., Altman J.K., Platanias L.C., An overview of themTOR pathway as a target in cancer therapy, Expert Opin. Ther.Targets, 2012, 16, 481-489.[Crossref]
• [12] Kim Y.J., Lee J., Song M.K., Han T., Ryu J.C., Valproic acidinhibits cell size and cell proliferation by AMPK-mediated mTORsignaling pathway in JEG-3 cells, BioChip J., 2013, 7, 267-277.[WoS][Crossref]
• [13] Eren Y., Özata A., Determination of mutagenic and cytotoxiceffects of Limonium globuliferum aqueous extracts by Allium,Ames, and MTT tests, Rev. Bras. Farmacogn., 2014, 24, doi:10.1590/0102-695X20142413322.[WoS][Crossref]
• [14] Morice L., Benaitreau D., Dieudonné M.N., Morvan C., SerazinV., de Mazancourt P., et al., Effets antiprolifératifs et proapoptotiquesdu bisphénol A dans les cellules trophoblastiqueshumaines JEG-3, Immuno-Anal. Biol. Spe., 2012, 27, 168-176.
• [15] Xu J.T., Zhao X., Yaster M., Tao Y.X., Expression and distributionof mTOR, p70S6K, 4E-BP1, and their phosphorylatedcounterparts in rat dorsal root ganglion and spinal cord dorsalhorn, Brain Res., 2010, 1336, 46-57.[WoS]
• [16] Lee D.Y., Li Y.S., Chang S.F., Zhou J., Ho H.M., Chiu J.J., et al.,Oscillatory flow-induced proliferation of osteoblast-like cellsis mediated by alpha vbeta3 and beta1 integrins throughsynergistic interactions of focal adhesion kinase and Shc withphosphatidylinositol 3-kinase and the Akt/mTOR/p70S6Kpathway, J. Biol. Chem., 2009, 285, 30-42.
• [17] Zheng J.H., Lu J.Q., Cheng M.J., Xu C.J., [Lung metastasisof human choriocarcinoma in mice: establishment ofexperimental metastatic model and its biological characteristics],Zhonghua Fu Chan Ke Za Zhi, 2010, 45, 519-524.
• [18] Sekine R., Hyodo M., Kojima M., Meguro Y., Suzuki A.,Yokoyama T., et al., Primary hepatic choriocarcinoma in a49-year-old man: report of a case, World J. Gastroenterol.,2014, 19, 9485-9489.[WoS]
• [19] Froeling F.E., Seckl M.J., Gestational Trophoblastic Tumours: AnUpdate for 2014, Curr. Oncol. Rep., 2014, 16, 408.[Crossref]
• [20] Berkowitz R.S., Goldstein D.P., Horowitz N.S. ManagementOptions of Gestational Trophoblastic Disease, Curr. Obstet.Gynecol. Rep., 2014, 3, 76-83.[Crossref]
• [21] Cole L.A., The hCG Group: the Key Molecules in HumanEvolution, Human Life, and Human Death, Curr. Obstet.Gynecol. Rep., 2014, 3, 91-101.[Crossref]
• [22] Strohl A.E., Lurain J.R., Clinical Epidemiology of GestationalTrophoblastic Disease, Curr. Obstet. Gynecol. Rep., 2014, 3,40-43.[Crossref]
• [23] Horn L.C., Einenkel J., Hoehn A.K., Classification andMorphology of Gestational Trophoblastic Disease, Curr. Obstet.Gynecol. Rep., 2014, 3, 44-54.[Crossref]
• [24] Nguyen N.M.P., Slim R., Genetics and Epigenetics of RecurrentHydatidiform Moles: Basic Science and Genetic Counselling,Curr. Obstet. Gynecol. Rep., 2014, 3, 55-64.[Crossref]
• [25] Shi D., Tan Z., Lu R., Yang W., Zhang Y., MicroRNA-218 inhibitsthe proliferation of human choriocarcinoma JEG-3 cell line bytargeting Fbxw8, Biochem. Bioph. Res. Co., 2014, 450, doi:10.1016/j.bbrc.2014.06.094.[Crossref]
• [26] Manguso F., Bennato R., Lombardi G., Viola A., Riccio E.,Picascia S., et al., P.15.6 DETERMINATION OF SERUM CORTISOLBY ECLIA UNDERSTIMATES SERUM CORTISOL SUPPRESSION INTHE PRESENCE OF PREDNISONE IN PATIENTS WITH UC. Digest,Liver Dis., 2014, 46, S112.
• [27] Liu C., Chen T., Lin J., Chen H., Chen J., Lin S., et al., Evaluationof the performance of four methods for detection of hepatitisB surface antigen and their application for testing 116,455specimens, J. Virol. Methods, 2014, 196, 174-178.[WoS]
• [28] Yang J., Sa M., Huang M., Yang J., Xiang Z., Liu B., et al., Thereference intervals for HE4, CA125 and ROMA in healthy femalewith electrochemiluminescence immunoassay, Clin. Biochem.,2013, 46, 1705-1708.[Crossref][WoS]
• [29] Garrett L.D., Canine mast cell tumors: diagnosis, treatment,and prognosis, Vet. Med. Res. Rep., 2014, 2014, 49-58.[Crossref]
• [30] Rasoulpour R.J., Terry C., LeBaron M.J., Stebbins K., Ellis-Hutchings R.G., Billington R., Mode-of-action and humanrelevance framework analysis for rat Leydig cell tumorsassociated with sulfoxaflor, Crit. Rev. Toxicol., 2014, 44, 25-44.[Crossref][WoS]

Identifiers

DOI

10.1515/med-2015-0039